{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:26:29Z","timestamp":1783571189974,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24fk0210103"],"award-info":[{"award-number":["JP24fk0210103"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"JSPS Grants-in-Aid for Scientific Research","doi-asserted-by":"crossref","award":["22K16023"],"award-info":[{"award-number":["22K16023"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Kumamoto University Hospital Young Researcher Activation Project","award":["R5-2"],"award-info":[{"award-number":["R5-2"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s10147-024-02616-x","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T11:22:39Z","timestamp":1726744959000},"page":"1908-1915","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical utility of a comprehensive genomic profiling test for patient with advanced biliary tract cancer"],"prefix":"10.1007","volume":"29","author":[{"given":"Hiroki","family":"Inada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Shinriki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisanobu","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Narahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Yoshinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuya","family":"Nagaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Yoshii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Fukubayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kisato","family":"Nosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2473-6966","authenticated-orcid":false,"given":"Yasuhito","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"2616_CR1","doi-asserted-by":"publisher","first-page":"e13","DOI":"10.1016\/j.cgh.2012.09.009","volume":"11","author":"N Razumilava","year":"2013","unstructured":"Razumilava N, Gores GJ (2013) Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol 11:e13\u2013e14","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2616_CR2","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.12998\/wjcc.v7.i14.1732","volume":"7","author":"JM Huguet","year":"2019","unstructured":"Huguet JM, Lobo M, Labrador JM et al (2019) Diagnostic-therapeutic management of bile duct cancer. World J Clin Cases 7:1732\u20131752","journal-title":"World J Clin Cases"},{"key":"2616_CR3","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","volume":"13","author":"JM Banales","year":"2016","unstructured":"Banales JM, Cardinale V, Carpino G et al (2016) Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol 13:261\u2013280","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2616_CR4","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1136\/gutjnl-2011-301748","volume":"61","author":"SA Khan","year":"2012","unstructured":"Khan SA, Davidson BR, Goldin RD et al (2012) Guidelines for the diagnosis and treatment of cholangiocarcinoma: An update. Gut 61:1657\u20131669","journal-title":"Gut"},{"key":"2616_CR5","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273\u20131281","journal-title":"N Engl J Med"},{"key":"2616_CR6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/jjco\/hyv213","volume":"46","author":"J Mizusawa","year":"2016","unstructured":"Mizusawa J, Morizane C, Okusaka T et al (2016) Randomized phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan clinical oncology group study (JCOG1113, FUGA-BT). Jpn J Clin Oncol 46:385\u2013388","journal-title":"Jpn J Clin Oncol"},{"key":"2616_CR7","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","volume":"30","author":"C Morizane","year":"2019","unstructured":"Morizane C, Okusaka T, Mizusawa J et al (2019) Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol 30:1950\u20131958","journal-title":"Ann Oncol"},{"key":"2616_CR8","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1002\/jhbp.1219","volume":"30","author":"T Ioka","year":"2023","unstructured":"Ioka T, Kanai M, Kobayashi S et al (2023) Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA). J Hepatobiliary Pancreat Sci 30:102\u2013110","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"2616_CR9","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3390\/life12060829","volume":"12","author":"CY Cheng","year":"2022","unstructured":"Cheng CY, Chen CP, Wu CE (2022) Precision medicine in cholangiocarcinoma: past, present, and future. Life 12:829","journal-title":"Life"},{"key":"2616_CR10","doi-asserted-by":"publisher","first-page":"820","DOI":"10.3390\/ijms23020820","volume":"23","author":"D Ciardiello","year":"2022","unstructured":"Ciardiello D, Maiorano BA, Parente P et al (2022) Immunotherapy for biliary tract cancer in the era of precision medicine: current knowledge and future perspectives. Int J Mol Sci 23:820","journal-title":"Int J Mol Sci"},{"key":"2616_CR11","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A et al (2020) Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 21:671\u2013684","journal-title":"Lancet Oncol"},{"key":"2616_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115383","volume":"9","author":"CR Churi","year":"2014","unstructured":"Churi CR, Shro R, Wang Y et al (2014) Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One 9:e115383","journal-title":"PLoS One"},{"key":"2616_CR13","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.3390\/cancers12082039","volume":"12","author":"S Chakrabarti","year":"2020","unstructured":"Chakrabarti S, Kamgar M, Mahipal A (2020) Targeted therapies in advanced biliary tract cancer: an evolving paradigm. Cancers 12:2039","journal-title":"Cancers"},{"key":"2616_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2021.100337","volume":"27","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Ricci AD, Brandi G et al (2021) Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma. Cancer Treat Res Commun 27:100337","journal-title":"Cancer Treat Res Commun"},{"key":"2616_CR15","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jhep.2020.03.007","volume":"73","author":"A Lamarca","year":"2020","unstructured":"Lamarca A, Barriuso J, McNamara MG et al (2020) Molecular targeted therapies: ready for \u201cprime time\u201d in biliary tract cancer. J Hepatol 73:170\u2013185","journal-title":"J Hepatol"},{"key":"2616_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","volume":"388","author":"L Goyal","year":"2023","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A et al (2023) Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med 388:228\u2013239","journal-title":"N Engl J Med"},{"issue":"8","key":"2616_CR17","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, He AR, Qin S et al (2022) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 1(8):EVIDoa2200015","journal-title":"NEJM Evid"},{"key":"2616_CR18","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1111\/liv.15641","volume":"43","author":"M Rimini","year":"2023","unstructured":"Rimini M, Fornaro L, Lonardi S et al (2023) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: an early exploratory analysis of real-world data. Liver Int 43:1803\u20131812","journal-title":"Liver Int"},{"issue":"1","key":"2616_CR19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12916-021-02089-z","volume":"19","author":"S Zhao","year":"2021","unstructured":"Zhao S, Zhang Z, Zhan J et al (2021) Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer. BMC Med 19(1):223","journal-title":"BMC Med"},{"issue":"4","key":"2616_CR20","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/S1470-2045(20)30074-7","volume":"21","author":"MJ Pishvaian","year":"2020","unstructured":"Pishvaian MJ, Blais EM, Brody JR et al (2020) Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial. Lancet Oncol 21(4):508\u2013518","journal-title":"Lancet Oncol"},{"key":"2616_CR21","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/onco.13844","volume":"26","author":"MA Israel","year":"2021","unstructured":"Israel MA, Danziger N, McGregor KA et al (2021) Comparative genomic analysis of intrahepatic cholangiocarcinoma: biopsy type, ancestry, and testing patterns. Oncologist 26:787\u2013796","journal-title":"Oncologist"},{"key":"2616_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.7664","volume":"11","author":"S Ishido","year":"2023","unstructured":"Ishido S, Tamaki N, Inada K et al (2023) Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test. Clin Case Rep 11:e7664","journal-title":"Clin Case Rep"},{"issue":"5","key":"2616_CR23","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/hepr.13875","volume":"53","author":"K Toshida","year":"2023","unstructured":"Toshida K, Itoh S, Yugawa K et al (2023) Prognostic significance for recurrence of fibroblast growth factor receptor 2 in intrahepatic cholangiocarcinoma patients undergoing curative hepatic resection. Hepatol Res 53(5):432\u2013439","journal-title":"Hepatol Res"},{"issue":"6","key":"2616_CR24","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1093\/jjco\/hyab029","volume":"51","author":"M Tsujie","year":"2021","unstructured":"Tsujie M, Iwai T, Kubo S et al (2021) Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma. Jpn J Clin Oncol 51(6):911\u2013917","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"2616_CR25","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1007\/s00535-020-01735-2","volume":"56","author":"Y Maruki","year":"2021","unstructured":"Maruki Y, Morizane C, Arai Y et al (2021) Molecular detection and clinicopathological characteristics of advanced\/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study). J Gastroenterol 56(3):250\u2013260","journal-title":"J Gastroenterol"},{"issue":"12","key":"2616_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.988527","volume":"2","author":"K Takada","year":"2022","unstructured":"Takada K, Kubo T, Kikuchi J et al (2022) Effect of comprehensive cancer genomic profiling on therapeutic strategies and clinical outcomes in patients with advanced biliary tract cancer: a prospective multicenter study. Front Oncol 2(12):988527","journal-title":"Front Oncol"},{"issue":"5","key":"2616_CR27","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s11523-023-00985-3","volume":"18","author":"D Zhang","year":"2023","unstructured":"Zhang D, Dorman K, Heinrich K et al (2023) A retrospective analysis of biliary tract cancer patients presented to the molecular tumor board at the Comprehensive Cancer Center Munich. Target Oncol 18(5):767\u2013776","journal-title":"Target Oncol"},{"issue":"3","key":"2616_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264138","volume":"17","author":"CA Milbury","year":"2022","unstructured":"Milbury CA, Creeden J, Yip WK et al (2022) Clinical and analytical validation of FoundationOne\u00aeCDx, a comprehensive genomic profiling assay for solid tumors. PLoS One 17(3):e0264138","journal-title":"PLoS One"},{"issue":"9","key":"2616_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237802","volume":"15","author":"R Woodhouse","year":"2020","unstructured":"Woodhouse R, Li M, Hughes J et al (2020) Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS One 15(9):e0237802","journal-title":"PLoS One"},{"issue":"1","key":"2616_CR30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13073-018-0547-0","volume":"10","author":"M Kato","year":"2018","unstructured":"Kato M, Nakamura H, Nagai M et al (2018) A computational tool to detect DNA alterations tailored to formalin-fixed paraffin-embedded samples in cancer clinical sequencing. Genome Med 10(1):44","journal-title":"Genome Med"},{"issue":"4","key":"2616_CR31","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1111\/cas.13969","volume":"110","author":"K Sunami","year":"2019","unstructured":"Sunami K, Ichikawa H, Kubo T et al (2019) Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: a hospital-based study. Cancer Sci 110(4):1480\u20131490","journal-title":"Cancer Sci"},{"issue":"595","key":"2616_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216997","volume":"28","author":"Y Ito","year":"2024","unstructured":"Ito Y, Yamada D, Kobayashi S et al (2024) The combination of gemcitabine plus an anti-FGFR inhibitor can have a synergistic antitumor effect on FGF-activating cholangiocarcinoma. Cancer Lett 28(595):216997","journal-title":"Cancer Lett"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02616-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02616-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02616-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T07:58:03Z","timestamp":1732607883000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02616-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["2616"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02616-x","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"assertion":[{"value":"7 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yasuhito Tanaka received honoraria from AbbVie GK, Gilead Sciences, Inc, Chugai Pharmaceutical Co., Ltd., ASKA Pharmaceutical Holdings Co., Ltd., OTSUKA Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., GlaxoSmithKline PLC, AstraZeneca, Eisai and HU frontier. He received research funds from AbbVie GK, FUJIREBIO Inc, Sysmex Corp, GlaxoSmithKline PLC., Gilead Sciences, Inc., Janssen Pharmaceutical K.K. and OTSUKA Pharmaceutical Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted following the ethical principles of the Declaration of Helsinki, and with the approval of the Ethics Committee of Kumamoto University (Approval No. 480).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}